Rhythm Pharmaceuticals Inc. 宣布，其针对获得性下丘脑肥胖症的3期Transcend临床试验结果，已获国际顶尖医学期刊《新英格兰医学杂志》发表。
该论文的发表，标志着该试验数据获得了权威医学界的正式认可与关注。研究聚焦于评估公司在研疗法对因下丘脑损伤导致严重肥胖患者群体的疗效与安全性。
获得性下丘脑肥胖是一种罕见且严重的疾病，常由脑部肿瘤、手术或创伤对下丘脑造成损伤引发。患者通常面临难以控制的体重增长、严重饥饿感及代谢紊乱，现有治疗选择极为有限。
此次在顶级期刊上公布详细数据，为后续与监管机构的沟通及潜在疗法的推进奠定了坚实的科学基础。公司期待这一进展能为深受该疾病困扰的患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.